Over 72 weeks, patients in the low-, medium- and high-dose orforglipron groups lost an average of 7.8%, 9.3% and 12.4% of their initial body weight, respectively, compared to 2.1% for the placebo group
Mostafavi, S
The result is a transient inflammatory state that can cause joint pain, fatigue, and general malaise during the active weight loss phase
Crispin was responsible for strategy, brand platform and positioning, visual design strategy, web, and media
A more stable glycemic profile supports consistent energy levels and reduces the metabolic drive to accumulate adipose tissue
The combination also has potential relevance for muscle growth protocols where researchers want to recompose body tissue rather than simply lose weight